Clinical and cost-effectiveness of eculizumab withdrawal in atypical haemolytic uraemic syndrome: the SETS aHUS multi-centre, open-label, prospective and single-arm study.
- DOI
- 10.3310/gjns4701
- Published
- 2026 Feb
- Container
- Health technology assessment (Winchester, England)
- Publisher
- Not recorded
- Open access
- yes
Credibility signals
limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- cautionDOI registered: No matching Crossref record was present in this response.
- cautionDOI resolves: No matching Crossref record was present in this response.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- supportingOpen access status: Normalized open-access status: open.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- cautionMetadata completeness: 5 of 6 scored descriptive metadata groups are present; missing fields increase uncertainty.
Cite this work
BibTeX
@article{allodium:10.3310/gjns4701,
title = {Clinical and cost-effectiveness of eculizumab withdrawal in atypical haemolytic uraemic syndrome: the SETS aHUS multi-centre, open-label, prospective and single-arm study.},
author = {Bryant A and Lecouturier J and Orozco-Leal G and Brocklebank V and Carnell S and Chadwick TJ and Dunn S and Johnson SA and Kavanagh D and Kennedy CA and Malina M and Montgomery EK and Muirhead CR and Oluboyede Y and Vale L and Weetman C and Kwan Soon Wong E and Woodward L and Sheerin NS},
year = {2026},
journal = {Health technology assessment (Winchester, England)},
doi = {10.3310/gjns4701},
url = {https://doi.org/10.3310/gjns4701}
}RIS
TY - JOUR TI - Clinical and cost-effectiveness of eculizumab withdrawal in atypical haemolytic uraemic syndrome: the SETS aHUS multi-centre, open-label, prospective and single-arm study. AU - Bryant A AU - Lecouturier J AU - Orozco-Leal G AU - Brocklebank V AU - Carnell S AU - Chadwick TJ AU - Dunn S AU - Johnson SA AU - Kavanagh D AU - Kennedy CA AU - Malina M AU - Montgomery EK AU - Muirhead CR AU - Oluboyede Y AU - Vale L AU - Weetman C AU - Kwan Soon Wong E AU - Woodward L AU - Sheerin NS PY - 2026 JO - Health technology assessment (Winchester, England) DO - 10.3310/gjns4701 UR - https://doi.org/10.3310/gjns4701 ER -
APA
A, B., J, L., G, O., V, B., S, C., TJ, C., S, D., SA, J., D, K., CA, K., M, M., EK, M., CR, M., Y, O., L, V., C, W., E, K. S. W., L, W., & NS, S. (2026). Clinical and cost-effectiveness of eculizumab withdrawal in atypical haemolytic uraemic syndrome: the SETS aHUS multi-centre, open-label, prospective and single-arm study.. Health technology assessment (Winchester, England). https://doi.org/10.3310/gjns4701
Source records
- pubmed · retrieved 2026-09-27T00:31:30.593Z